Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/18/21 (What's New)

Summary

  • Several trials have been undertaken to address the safety and efficacy of modifying NNRTI-based regimens to both 3-drug dolutegravir-based regimens and 2-drug INSTI regimens

Action required